TickerFacts.

Company research / RGEN

Repligen Corp (RGEN)

Build a valuation ↗↓ Download CSV

SEC name REPLIGEN CORP · CIK 0000730272 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends around Dec 31

For the year ended 2025-12-31, Repligen Corp reported revenue of $738.26M. Revenue grew 16.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $785.10M.

Key ratios (year ended 2025-12-31)

52.3%
Gross margin (computed)
7.5%
Operating margin
6.6%
Net margin
2.3%
Return on year-end equity
16.4%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-08

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$785.10M$738.26M$634.44M$632.36M$801.54M$670.53M$366.26M$270.25M$194.03M$141.24M$104.54M
Cost of Revenuen/a$352.01M$359.79M$353.92M$345.83M$279.28M$156.63M$119.10M$86.53M$67.05M$47.12M
Gross Profit (computed)n/a$386.25M$274.64M$278.44M$455.71M$391.25M$209.63M$151.15M$107.50M$74.19M$57.42M
R&D Expensen/a$54.18M$43.20M$42.72M$43.94M$34.27M$20.18M$19.45M$15.82M$8.67M$7.36M
Operating Income$64.61M$55.17M-$35.11M$47.70M$224.67M$167.25M$69.82M$36.08M$25.99M$14.01M$15.97M
Depreciation & Amortization$78.78M$78.75M$69.67M$68.56M$50.98M$38.45M$27.07M$20.87M$15.78M$10.51M$5.33M
EBITDA$143.39M$133.91M$34.56M$116.26M$275.65M$205.70M$96.89M$56.95M$41.77M$24.51M$21.31M
Net Income$41.54M$48.89M-$25.51M$35.60M$185.96M$128.29M$59.93M$21.41M$16.62M$28.35M$11.68M
EPS (Diluted)n/a$0.86-$0.46$0.63$3.24$2.24$1.11$0.44$0.37$0.72$0.34
Total Assets$2.95B$2.95B$2.83B$2.83B$2.53B$2.36B$1.90B$1.40B$774.62M$743.52M$288.91M
Total Liabilities$838.15M$843.57M$856.95M$866.34M$620.90M$608.29M$373.74M$340.35M$159.05M$151.97Mn/a
Long-Term Debt$551.05M$542.21M$525.57Mn/an/an/an/an/an/an/an/a
Shareholders' Equity$2.11B$2.11B$1.97B$1.96B$1.91B$1.75B$1.53B$1.06B$615.57M$591.55M$168.76M
Cash & Equivalents$606.78M$566.02M$757.36M$751.32M$523.46M$603.81M$717.29M$528.39M$193.82M$173.76M$122.23M
Operating Cash Flow$134.86M$117.42M$175.39M$113.92M$172.08M$119.02M$62.62M$67.22M$32.77M$17.45M$7.52M
Capital Expenditures$22.90M$23.52M$25.68M$36.22M$84.83M$67.09M$22.45M$18.50M$10.63M$5.45M$4.33M
Free Cash Flow$111.97M$93.90M$149.72M$77.70M$87.25M$51.93M$40.17M$48.71M$22.14M$12.00M$3.20M
Share Repurchasesn/a$0$0$14.39M$0$0n/an/an/an/an/a
Shares Outstanding56.43M56.33M56.09M55.77M55.56M55.32M54.76M52.08M43.92M43.59M33.84M
Weighted Average Diluted Sharesn/an/an/an/an/a57.26M53.89M49.21M45.47M39.15M34.10M
EPS (Basic)n/a$0.87-$0.46$0.64$3.35$2.33$1.14$0.44$0.38$0.74$0.35

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView